BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions GlobeNewswire - Tue Apr 13, 6:45AM CDT CMTX - Tue Apr 13, 6:45AM CDT
BridgeBio Pharma, Inc. (NASDAQ: BBIO), and the University of California, San Diego (UC San Diego) today announced a partnership to translate research in genetically driven conditions into potential therapeutic...
BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases GlobeNewswire - Tue Apr 13, 6:42AM CDT CMTX - Tue Apr 13, 6:42AM CDT
BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with the University of California, Davis (UC Davis), to advance research and the development of investigational medicines for patients...
BridgeBio Pharma, Inc. and Roswell Park Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Cancers GlobeNewswire - Tue Apr 13, 6:40AM CDT CMTX - Tue Apr 13, 6:40AM CDT
BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Roswell Park Comprehensive Cancer Center to advance the development of investigational therapeutics for patients with genetically...
BridgeBio Pharma, Inc. and Oregon Health & Science University Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Diseases GlobeNewswire - Tue Apr 13, 6:37AM CDT CMTX - Tue Apr 13, 6:37AM CDT
BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Oregon Health & Science University (OHSU) in Portland, Oregon, to advance research and the development of investigational medicines...
BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers GlobeNewswire - Tue Apr 13, 6:35AM CDT CMTX - Tue Apr 13, 6:35AM CDT
BridgeBio Pharma, Inc. (NASDAQ: BBIO) and The Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center today announced a collaboration to translate research in genetically driven...
BridgeBio Pharma, Inc. and GlycoNet Initiate Collaboration to Discover Potential Treatments for Genetic Diseases through Glycomics Research GlobeNewswire - Tue Apr 13, 6:32AM CDT CMTX - Tue Apr 13, 6:32AM CDT
BridgeBio Pharma, Inc. (NASDAQ: BBIO) and the Canadian Glycomics Network (GlycoNet), a pan-Canadian Network of Centres of Excellence, today announced a collaboration to translate scientific research in...
BridgeBio Pharma and Brown University Announce Partnership to Drive the Advancement of Academic Innovations in Genetically Driven Diseases into Potential Therapeutics for Patients GlobeNewswire - Tue Apr 13, 6:30AM CDT CMTX - Tue Apr 13, 6:30AM CDT
BridgeBio Pharma, Inc. (NASDAQ: BBIO), and Brown University today announced a formal collaboration to advance research in genetically driven neurological disorders into potential life-changing medicines...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Apr 6, 3:30PM CDT CMTX - Tue Apr 6, 3:30PM CDT
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on April 5, 2021, the compensation committee of BridgeBio's board of...
BridgeBio Pharma's Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology GlobeNewswire - Wed Mar 31, 6:30AM CDT CMTX - Wed Mar 31, 6:30AM CDT
- BridgeBio, through its affiliate QED ("BridgeBio"), and Helsinn to co-commercialize infigratinib for oncology and all other indications other than skeletal dysplasia indications in the U.S. and equally...
BridgeBio Pharma Announces Proof-of-Concept Data of Encaleret in ADH1 at the Endocrine Society's 2021 Annual Meeting GlobeNewswire - Sat Mar 20, 10:00AM CDT CMTX - Sat Mar 20, 10:00AM CDT
- Normalization of Blood Calcium and Urine Calcium in 6 of 6 (100%) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Participants Initially Evaluated Over 5 Days Demonstrates Proof-of-Concept
NASDAQ Down for 2021 as Stocks Drop for a Third Day Zacks - Fri Mar 5, 12:15AM CST Jim Giaquinto - ZACKS - Fri Mar 5, 12:15AM CST
NASDAQ Down for 2021 as Stocks Drop for a Third Day
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Mar 2, 3:30PM CST CMTX - Tue Mar 2, 3:30PM CST
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 1, 2021, the compensation committee of BridgeBio's board of...
BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY(TM) (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A GlobeNewswire - Sun Feb 28, 7:00AM CST CMTX - Sun Feb 28, 7:00AM CST
Molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly, results in severe and largely irreversible neurological injury, and has a high infant...
Is a Surprise Coming for BridgeBio Pharma (BBIO) This Earnings Season? Zacks - Fri Feb 26, 7:46AM CST Zacks Equity Research - ZACKS - Fri Feb 26, 7:46AM CST
BridgeBio Pharma (BBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue Estimates Zacks - Thu Feb 25, 8:05AM CST Zacks Equity Research - ZACKS - Thu Feb 25, 8:05AM CST
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -17.44% and -99.21%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma: 4Q Earnings Snapshot AP - Thu Feb 25, 7:07AM CST APAI - Thu Feb 25, 7:07AM CST
PALO ALTO, Calif. (AP) _ BridgeBio Pharma Inc. (BBIO) on Thursday reported a loss of $120 million in its fourth quarter.
BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update GlobeNewswire - Thu Feb 25, 6:31AM CST CMTX - Thu Feb 25, 6:31AM CST
-Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory approval...
BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society's 2021 Annual Meeting GlobeNewswire - Wed Feb 24, 3:01PM CST CMTX - Wed Feb 24, 3:01PM CST
BridgeBio Pharma, Inc. (Nasdaq: BBIO),�?�a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers...
Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for Zacks - Mon Feb 22, 11:30AM CST Zacks Equity Research - ZACKS - Mon Feb 22, 11:30AM CST
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stocks Still Near All-Time Highs Despite Sluggish Week Zacks - Sat Feb 20, 12:15AM CST Jim Giaquinto - ZACKS - Sat Feb 20, 12:15AM CST
Stocks Still Near All-Time Highs Despite Sluggish Week
